A chimeric anti-ENO1 monoclonal antibody (ChenO1-22) can attenuate cancer cell invasion by inhibiting ENO1-mediated GSK3β inactivation to promote SLUG protein ubiquitination and block metastasis (27). This evidence concerns the gene ENO1 and cancer.